These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31751307)

  • 1. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data.
    Aydemirli MD; Kapiteijn E; Ferrier KRM; Ottevanger PB; Links TP; van der Horst-Schrivers ANA; Broekman KE; Groenwold RHH; Zwaveling J
    Eur J Endocrinol; 2020 Feb; 182(2):131-138. PubMed ID: 31751307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
    Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
    Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
    J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
    Kiyota N; Schlumberger M; Muro K; Ando Y; Takahashi S; Kawai Y; Wirth L; Robinson B; Sherman S; Suzuki T; Fujino K; Gupta A; Hayato S; Tahara M
    Cancer Sci; 2015 Dec; 106(12):1714-21. PubMed ID: 26426092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life.
    Marotta V; Rocco D; Crocco A; Deiana MG; Martinelli R; Di Gennaro F; Valeriani M; Valvano L; Caleo A; Pezzullo L; Faggiano A; Vitale M; Monti S
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2541-2552. PubMed ID: 38501238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
    Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
    Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Wirth LJ
    Eur J Cancer; 2021 Apr; 147():51-57. PubMed ID: 33611104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
    Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
    Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States.
    Worden F; Rajkovic-Hooley O; Reynolds N; Milligan G; Zhang J
    Endocrine; 2024 May; 84(2):663-669. PubMed ID: 38102498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten years' real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer.
    Jerkovich F; Capalbo S; Abelleira E; Pitoia F
    Endocrine; 2024 Aug; 85(2):817-826. PubMed ID: 38772990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
    Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
    Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
    Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
    Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
    [No Abstract]   [Full Text] [Related]  

  • 17. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
    Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
    Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.